Article

Alcon unveils trio of new product offerings

Alcon Laboratories rolls out several extensions to its product offerings, including the AcrySof toric IOL, DisCoVisc ophthalmic viscosurgical device (OVD), and Systane Free lubricant eye drops.

Alcon Laboratories rolls out several extensions to its product offerings, including the AcrySof toric IOL, DisCoVisc ophthalmic viscosurgical device (OVD), and Systane Free lubricant eye drops.

The AcrySof toric IOL provides unparalleled rotational stability to correct astigmatism precisely, according to the company. This results in distance-vision spectacle freedom for cataract patients with pre-existing astigmatism. The single-piece natural IOL also filters ultraviolet and blue light.

The DisCoVisc OVD is formulated to be what the company claims is the "first viscous dispersive in the marketplace." The OVD provides a unique combination of sodium chondroitin sulfate and sodium hyaluronate that have demonstrated superior results during virtually all phases of the cataract procedure, according to Alcon.

Systane Free lubricant eye drops are an extension to the company's line of dry eye treatments. The new formulation provides patients with long-lasting relief from the signs and symptoms of dry eye with less blurring following instillation. In addition, the formula contains a unique ionic buffer self-preservation system.

For more information, visit Alcon Laboratories at Booths 1926 and 2226.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.